Robert C. Bast
Affiliations: | Department of Experimental Therapeutics | University of Texas M.D. Anderson Cancer Center |
Google:
"Robert Bast"Mean distance: (not calculated yet)
Collaborators
Sign in to add collaborator| Ching-Wei Lin | collaborator | 2015-2017 | University of Texas M.D. Anderson Cancer Center |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Wang F, Yu X, Qian J, et al. (2024) A novel SIK2 inhibitor SIC-19 exhibits synthetic lethality with PARP inhibitors in ovarian cancer. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 74: 101077 |
| Handley KF, Sims TT, Bateman NW, et al. (2022) Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics. Jama Network Open. 5: e2236626 |
| Irajizad E, Han CY, Celestino J, et al. (2022) A blood-based metabolite panel for distinguishing ovarian cancer from benign pelvic masses. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Boylan KLM, Petersen A, Starr TK, et al. (2022) Development of a Multiprotein Classifier for the Detection of Early Stage Ovarian Cancer. Cancers. 14 |
| Shi X, Yu X, Wang J, et al. (2022) SIK2 promotes ovarian cancer cell motility and metastasis by phosphorylating MYLK. Molecular Oncology |
| Blackman A, Mitchell J, Rowswell-Turner R, et al. (2021) Analysis of serum HE4 levels in various histologic subtypes of epithelial ovarian cancer and other malignant tumors. Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine. 43: 355-365 |
| Bast RC, Han CY, Lu Z, et al. (2021) Next steps in the early detection of ovarian cancer. Communications Medicine. 1 |
| Bildik G, Liang X, Sutton MN, et al. (2021) DIRAS3: An Imprinted tumor suppressor gene that regulates RAS and PI3K-driven cancer growth, motility, autophagy and tumor dormancy. Molecular Cancer Therapeutics |
| Artibani M, Masuda K, Hu Z, et al. (2021) Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor initiating cells. Jci Insight |
| Fan D, Yang H, Mao W, et al. (2021) A Novel Salt Inducible Kinase 2 Inhibitor, ARN-3261, Sensitizes Ovarian Cancer Cell Lines and Xenografts to Carboplatin. Cancers. 13 |